Business Context and Reporting Period
Company: Labcorp Holdings Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: A global leader in laboratory services operating through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). Dx contributed approximately 78% of revenues, while BLS contributed 22%.
Key Financial Metrics
| Metric (in millions) | Q2 2026 | Q2 2025 | YTD 2026 | YTD 2025 |
|---|---|---|---|---|
| Revenues | $3,731.1 | $3,527.3 | $7,268.7 | $6,872.4 |
| Operating Income | $451.6 | $394.5 | $832.4 | $720.5 |
| Net Earnings (Attributable to LHI) | $298.7 | $237.9 | $576.5 | $450.7 |
| Diluted EPS | $3.64 | $2.84 | $6.99 | $5.36 |
| Operating Cash Flow (YTD) | $637.0 | $639.1 | $637.0 | $639.1 |
| Cash and Equivalents (End of Period) | $141.8 | $647.3 | $141.8 | $647.3 |
| Total Debt (Long-term + Current) | $5,858.5 | $5,584.7 | $5,858.5 | $5,584.7 |
Note: Total Debt calculated as Long-term debt ($5,857.6) plus Short-term borrowings ($0.9) as of June 30, 2026.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 5.8% year-over-year for both the quarter and the six-month period. Growth was driven by organic revenue (4.2% for Q2, 3.6% YTD), acquisitions (1.2% for Q2, 1.3% YTD), and favorable foreign currency translation.
- Profitability: Operating income rose 14.5% for the quarter and 15.5% YTD. Both Dx and BLS segments improved operating margins due to organic growth and operating efficiencies.
- Debt Restructuring: The company entered a new $750.0 million Term Loan in March 2026 and used proceeds to redeem $500.0 million of 1.55% senior notes due in 2026. Total debt increased slightly due to the new term loan and AR Facility activity.
- Cash Position: Cash and cash equivalents decreased significantly from $532.3 million to $141.8 million, primarily due to $427.9 million in acquisition payments and $451.8 million in share repurchases.
- Acquisitions: The company acquired various businesses for total consideration of $528.6 million (net of cash) in the first half of 2026, recording $262.1 million in goodwill.
Guidance, Outlook, and Risks
- Share Repurchases: The Board authorized an additional $1,000.0 million in share repurchases on July 8, 2026, bringing the total authorization to $1,378.6 million. The company repurchased $451.8 million of stock YTD 2026.
- Dividends: A quarterly dividend of $0.72 per share was declared on July 9, 2026, payable September 11, 2026.
- Regulatory Risks: The company notes potential impacts from the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025, which could affect Medicaid and federal funding, potentially reducing utilization of diagnostics services.
- Legal Contingencies:
- Texas Medicaid: The Texas Supreme Court reinstated a District Court judgment in favor of Labcorp regarding "best price" regulations in June 2026.
- Ravgen Patent: A jury previously awarded $272.0 million in damages plus enhancements. Labcorp is appealing the verdict and has posted a bond to stay enforcement.
- AMCA Data Incident: A class action settlement regarding the 2019 AMCA security incident was reached in March 2026, subject to court approval.
- Outlook: Management expects to remain compliant with debt covenants for the next 12 months and believes liquidity is sufficient for short- and long-term needs.
Investor Verification Checklist
- Debt Maturity Profile: Verify the impact of the new $750.0 million Term Loan (maturing 2028) on future interest expense and leverage ratios.
- Acquisition Integration: Monitor the integration of $528.6 million in acquisitions and the realization of expected synergies.
- Legal Exposure: Track the status of the Ravgen patent appeal and the final court approval of the AMCA class action settlement.
- Regulatory Impact: Assess the actual financial impact of the OBBBA legislation on Medicaid reimbursement and patient volume.
- Cash Flow Sustainability: Evaluate the ability to maintain operating cash flows while funding significant capital expenditures ($252.6 million YTD) and aggressive share buybacks.